Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2022 16:00 ET | Source: Virogin Biotech

Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors

VANCOUVER, British Columbia, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study...